The Minister of Health, Luis Quirozrated as “Seriously” that insulin withdrawn from the national market continues to be marketed despite the official suspension order from the General Directorate of Medicines, Supplies and Drugs (Digemid).
The warning came after the journalistic complaint by end pointwhich revealed the durability of the sale of insulin with Health record rejected, putting patients and authorities on alert.
The Health Authority announced that operations in pharmacies and hospitals will be intensified to prevent the distribution of the insulin observed, in strict compliance with established safety protocols.
insulin Wosulin-Nof Indian origin, was withdrawn after discovery had serious irregularities in the manufacturing processreported the Ministry of Health (Minsa).
The drug prepared by the laboratory Wockhardt Limitedwas distributed in Hospitals and pharmacies publicly available and is considered essential for the management of diabetes in the country.
The recall of this product was subsequently determined Digemid will identify data manipulation, presence of contaminants, possible toxins and deficiencies in good manufacturing practices.
Despite the order, as found end pointSeveral pharmacies in the Lima metropolitan area continue to offer the recalled insulin, which poses a potential danger to the population 1.3 million people with diabetes over 20 years old in Peru.
During a hospital visit Casimiro Ulloa in Miraflores, Luis Quiroz assured that “All products that do not have health registration have been removed” and explained that only those insulins that have passed quality controls and analytical tests remain in pharmacies.
However, he confirmed this in his response to questions from RPP News The “If there is a product that continues to be sold, then it is serious. Measures are being taken across the city today to ensure compliance.”.
The decision to immobilize the product and withdraw it from the market was based on previous health warnings and sparked concern among mothers of children with diabetes who reported the persistence of insulin discontinuation in public hospitals. Civil organizations such as NGOs Lucas, a life’s workcalled for the strict application of regulations to ensure security of access to medicines.
In a statement released after the report by End pointHe Minsa suggested that insulin Wosulin-N and other drugs of similar risk have undergone a “Certificate of Compliant Analysis” before use and that the batches used have had a health protocol during the validity period.
Following a technical inspection conducted in India in September 2025, the health authority found that observations in the manufacturer’s processes were not corrected, leading to the definitive suspension of registration under the regulation Law No. 29459.
The Ministry of Health itself highlighted this in its official response “We will not allow the use of medicines that do not ensure 100% compliance with Good Manufacturing Practices.”a message aimed at both retailers and healthcare facilities.
The statement added that there are sufficient stocks of approved insulins and that the continuity of treatments is guaranteed by products certified by countries with high health surveillance.
The case of the recalled insulin highlights a broader problem in the national health system. The investigation of endpoint revealed the existence of at least 277 medications banned or suspended in public hospitals and health centers, many of them are widely used to treat pathologies such as cancer, infections, cardiovascular diseases, HIV and mental disorders.
The representative of Medical School of Peru, Victor Dongoexpressed concern about the proliferation of medicines without adequate controls. In statements on Sunday, he said such a situation could “cause fatal problems” and recalled that dozens of products had failed testing Digemid before marketing.
The gap between regulations and effective distribution has created a demand for stricter measures and coordination between entities such as: B. increased EsSalud, Digemid and the Minsa Monitoring entry, storage and dispensing in both the public and private sectors.
He Ministry of Health repeated, collected in statements by RPP Newsthe instruction to carry out constant monitoring in pharmacies and hospitals to detect any violations of the related regulations vital medicines.
Human insulin is still considered a safe therapeutic alternativeprovided that the applicable health registration framework and international guidelines recommended by health authorities are adhered to.
The insulin case Wosulin-N It remains under the supervision of regulators while operations and control investigations in the national drug circuit continue.
About The Author
